ro 8-0576 has been researched along with Disease Models, Animal in 14 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (7.14) | 29.6817 |
| 2010's | 11 (78.57) | 24.3611 |
| 2020's | 2 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Al-Kaleel, A; Aygün, H; Erbaş, O | 1 |
| Chen, S; Duan, S; Fang, J; Le, Y; Li, D; Li, F; Qing, W; Tan, L; Tong, J; Wang, Y; Yang, J; Zhang, B | 1 |
| Chen, NH; Heng, Y; Huang, JY; Mou, Z; Yuan, YH; Zhang, QS | 1 |
| Iggena, D; Klein, C; Rasińska, J; Sparenberg, M; Steiner, B; Winter, Y | 1 |
| Bezard, E; De Deurwaerdere, P; Li, Q; Marti, M; Meissner, WG; Morari, M; Morgenstern, R; Porras, G; Sohr, R | 1 |
| Di Paolo, T; Grégoire, L; Morin, N; Morissette, M | 1 |
| Kuric, E; Ruscher, K | 1 |
| De Wolf, C; Downey, P; Michel, A; Scheller, D; Schwarting, R; Van Damme, X | 1 |
| Aubert, I; Berton, O; Bezard, E; Bioulac, BH; Dileone, RJ; Gross, CE; Guigoni, C; Li, Q; Nestler, EJ | 1 |
| Alachkar, A; Brotchie, JM; Jones, OT | 1 |
| Egeland, M; Svenningsson, P; Zhang, X | 1 |
| Cai, Y; Liu, Z; Ren, T; Wu, N; Yang, X; Yuan, W | 1 |
| Asada, M; Asada, N; Fehling, HJ; Fukatsu, A; Kimura, T; Kita, T; Minegishi, N; Nagoshi, N; Nakamura, J; Oguchi, A; Okano, H; Rao, TN; Shibata, S; Suzuki, N; Takase, M; Yamamoto, M; Yamamura, K; Yanagita, M | 1 |
| Chen, Y; Hong, X; Liu, Z; Song, L; Wu, N; Yang, X; Yuan, W | 1 |
14 other study(ies) available for ro 8-0576 and Disease Models, Animal
| Article | Year |
|---|---|
The effect of Madopar on absence‑like seizures in WAG/Rij rats.
Topics: Animals; Benserazide; Disease Models, Animal; Drug Combinations; Electroencephalography; Epilepsy, Absence; Levodopa; Male; Rats; Rats, Wistar; Seizures | 2022 |
Small dose of L-dopa/Benserazide hydrochloride improved sepsis-induced neuroinflammation and long-term cognitive dysfunction in sepsis mice.
Topics: Animals; Benserazide; Brain; Cognitive Dysfunction; Disease Models, Animal; Drug Combinations; Hippocampus; Levodopa; Male; Mice; Mice, Inbred C57BL; Neuroimmunomodulation; Receptors, Dopamine D1; Receptors, Dopamine D2; Sepsis; Sepsis-Associated Encephalopathy | 2020 |
Reassessment of subacute MPTP-treated mice as animal model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; alpha-Synuclein; Animals; Antiparkinson Agents; Astrocytes; Behavior, Animal; Benserazide; Benzothiazoles; Blood-Brain Barrier; Chromatography, High Pressure Liquid; Corpus Striatum; Disease Models, Animal; Drug Combinations; Levodopa; Male; Mice; Mice, Inbred C57BL; Microscopy, Electron; Parkinsonian Disorders; Pramipexole; Selegiline | 2017 |
Physical activity sustains memory retrieval in dopamine-depleted mice previously treated with L-Dopa.
Topics: Animals; Antiparkinson Agents; Benserazide; Corpus Striatum; Disease Models, Animal; Dopamine; Drug Combinations; Female; Green Fluorescent Proteins; Hippocampus; Levodopa; Maze Learning; Memory; Mice, Inbred C57BL; Mice, Transgenic; Motor Activity; MPTP Poisoning; Neurogenesis; Random Allocation; Sedentary Behavior | 2019 |
L-dopa-induced dyskinesia: beyond an excessive dopamine tone in the striatum.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Benserazide; Corpus Striatum; Disease Models, Animal; Dopamine; Dopamine Agents; Drug Combinations; Dyskinesias; Female; Levodopa; Macaca mulatta; Male; Parkinson Disease | 2014 |
Effect of a chronic treatment with an mGlu5 receptor antagonist on brain serotonin markers in parkinsonian monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Benserazide; Brain; Disease Models, Animal; Dopamine; Dopamine Agents; Dose-Response Relationship, Drug; Drug Combinations; Dyskinesia, Drug-Induced; Excitatory Amino Acid Antagonists; Female; Homovanillic Acid; Levodopa; Macaca fascicularis; Ovariectomy; Parkinsonian Disorders; Protein Binding; Pyridines; Serotonin | 2015 |
Dynamics of major histocompatibility complex class II-positive cells in the postischemic brain--influence of levodopa treatment.
Topics: Animals; Antigen-Presenting Cells; Benserazide; Brain; Cytokines; Disease Models, Animal; Dopamine Agents; Drug Combinations; Flow Cytometry; Functional Laterality; Histocompatibility Antigens Class II; Infarction, Middle Cerebral Artery; Levodopa; Macrophages; Male; Microglia; Rats; Rats, Sprague-Dawley; Rats, Wistar | 2014 |
Behavioural Assessment of the A2a/NR2B Combination in the Unilateral 6-OHDA-Lesioned Rat Model: A New Method to Examine the Therapeutic Potential of Non-Dopaminergic Drugs.
Topics: Adenosine A2 Receptor Antagonists; Animals; Benserazide; Benzothiazoles; Disease Models, Animal; Dopamine; Dopamine Agents; Drug Combinations; Levodopa; Male; Motor Activity; Oxidopamine; Parkinson Disease; Rats; Receptors, N-Methyl-D-Aspartate | 2015 |
Striatal overexpression of DeltaJunD resets L-DOPA-induced dyskinesia in a primate model of Parkinson disease.
Topics: Analysis of Variance; Animals; Antiparkinson Agents; Benserazide; Corpus Striatum; Disease Models, Animal; Dopamine Plasma Membrane Transport Proteins; Drug Combinations; Dyskinesia, Drug-Induced; Female; Gene Expression Regulation; Genetic Therapy; Genetic Vectors; Green Fluorescent Proteins; Humans; Iodine Radioisotopes; Levodopa; Linear Models; Macaca fascicularis; Male; MPTP Poisoning; Nortropanes; Protein Binding; Proto-Oncogene Proteins c-jun; Radionuclide Imaging; RNA, Messenger | 2009 |
Locomotor response to L-DOPA in reserpine-treated rats following central inhibition of aromatic L-amino acid decarboxylase: further evidence for non-dopaminergic actions of L-DOPA and its metabolites.
Topics: Adrenergic alpha-Antagonists; Adrenergic Uptake Inhibitors; Animals; Aromatic Amino Acid Decarboxylase Inhibitors; Aromatic-L-Amino-Acid Decarboxylases; Benserazide; Brain Chemistry; Disease Models, Animal; Dopamine Agents; Drug Combinations; Dyskinesia, Drug-Induced; Enzyme Inhibitors; Hydrazines; Hyperkinesis; Levodopa; Male; Motor Activity; Rats; Rats, Sprague-Dawley; Reserpine; Serotonin Receptor Agonists | 2010 |
Antidepressant-like properties of sarizotan in experimental Parkinsonism.
Topics: Animals; Antidepressive Agents; Antiparkinson Agents; Behavior, Animal; Benserazide; Cell Proliferation; Dentate Gyrus; Depression; Disease Models, Animal; Doublecortin Protein; Drug Combinations; Levodopa; Locomotion; Male; Organic Chemicals; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Swimming | 2011 |
Sustained-release formulation of levodopa methyl ester/benserazide for prolonged suppressing dyskinesia expression in 6-OHDA-leisoned rats.
Topics: Animals; Antiparkinson Agents; Benserazide; Delayed-Action Preparations; Disease Models, Animal; Dopamine Agents; Drug Combinations; Levodopa; Male; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Wistar; Reaction Time | 2011 |
Dysfunction of fibroblasts of extrarenal origin underlies renal fibrosis and renal anemia in mice.
Topics: Anemia; Animals; Benserazide; Cell Differentiation; Cell Lineage; Disease Models, Animal; Drug Combinations; Erythropoietin; Female; Fibroblasts; Fibrosis; Kidney; Levodopa; Mice; Mice, Transgenic; Myofibroblasts; Pregnancy | 2011 |
Levodopa/benserazide microspheres reduced levodopa-induced dyskinesia by downregulating phosphorylated GluR1 expression in 6-OHDA-lesioned rats.
Topics: Animals; Antiparkinson Agents; Benserazide; Blotting, Western; Delayed-Action Preparations; Disease Models, Animal; Down-Regulation; Drug Carriers; Drug Combinations; Dyskinesia, Drug-Induced; Female; Lactic Acid; Levodopa; Microspheres; Oxidopamine; Parkinsonian Disorders; Phosphorylation; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Rats; Rats, Sprague-Dawley; Real-Time Polymerase Chain Reaction; Receptors, AMPA | 2012 |